Protagenic Interest Income from 2010 to 2026

Stocks . USA . 
Stock . Protagenic Therapeutics
PTIXW Stock  USD 0.03  0.03  685.00%   
Protagenic Therapeutics Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income will likely drop to about 47.5 K in 2026. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals
 
Interest Income  
First Reported
2020-03-31
Previous Quarter
8.1 K
Current Value
34.3 K
Quarterly Volatility
27.5 K
 
Covid
 
Interest Hikes
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 43 K, Interest Expense of 0.0 or Selling General Administrative of 1.5 M, as well as many indicators such as Price To Sales Ratio of 3.0E-4, Dividend Yield of 0.0 or PTB Ratio of 31.35. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Protagenic Stock
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.
The evolution of Interest Income for Protagenic Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Protagenic Therapeutics compares to historical norms and industry peers.

Latest Protagenic Therapeutics' Interest Income Growth Pattern

Below is the plot of the Interest Income of Protagenic Therapeutics over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Protagenic Therapeutics' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Interest Income10 Years Trend
Pretty Stable
Compare to OthersAll Fundamentals
   Interest Income   
       Timeline  

Protagenic Interest Income Regression Statistics

Arithmetic Mean96,859
Geometric Mean58,685
Coefficient Of Variation106.44
Mean Deviation81,065
Median42,320
Standard Deviation103,097
Sample Variance10.6B
Range332.4K
R-Value0.25
Mean Square Error10.6B
R-Squared0.06
Significance0.33
Slope5,156
Total Sum of Squares170.1B

Protagenic Interest Income History

202647.5 K
202550 K
202443.5 K
2023303.2 K
2022185.8 K
202133.2 K
2020 2870.0

Other Fundumenentals of Protagenic Therapeutics

Net Interest Income

Protagenic Therapeutics Interest Income component correlations

Total Assets
Total Stockholder Equity
Net Debt
Retained Earnings
Net Receivables
Good Will
Total Liab
Total Current Assets
Short Term Debt
Common Stock
Accounts Payable
Short Term Investments
Intangible Assets
Current Deferred Revenue
Net Invested Capital
Net Working Capital
Capital Stock
Long Term Debt
Capital Surpluse
Short Long Term Debt
Total Assets
0.610.070.18-0.57-0.57-0.130.920.14-0.2-0.140.81-0.410.580.740.740.17-0.150.120.12
Total Stockholder Equity
0.61-0.480.87-0.23-0.23-0.870.6-0.66-0.9-0.870.46-0.130.270.460.46-0.010.01-0.05-0.05
Net Debt
0.07-0.48-0.5-0.42-0.420.65-0.060.660.60.640.14-0.410.330.00.010.280.040.350.35
Retained Earnings
0.180.87-0.5-0.13-0.13-0.970.14-0.84-0.98-0.970.07-0.070.150.050.05-0.010.1-0.02-0.02
Net Receivables
-0.57-0.23-0.42-0.131.0-0.07-0.24-0.420.03-0.06-0.160.81-0.950.030.02-0.170.17-0.4-0.4
Good Will
-0.57-0.23-0.42-0.131.0-0.07-0.24-0.420.03-0.06-0.160.82-0.940.030.02-0.170.17-0.4-0.4
Total Liab
-0.13-0.870.65-0.97-0.07-0.07-0.160.910.991.0-0.07-0.10.02-0.11-0.110.13-0.110.140.14
Total Current Assets
0.920.6-0.060.14-0.24-0.24-0.16-0.02-0.2-0.170.93-0.20.220.920.920.18-0.130.110.11
Short Term Debt
0.14-0.660.66-0.84-0.42-0.420.91-0.020.860.91-0.02-0.310.41-0.1-0.10.06-0.160.120.12
Common Stock
-0.2-0.90.6-0.980.030.030.99-0.20.861.0-0.08-0.03-0.08-0.11-0.10.11-0.140.130.13
Accounts Payable
-0.14-0.870.64-0.97-0.06-0.061.0-0.170.911.0-0.07-0.090.01-0.11-0.10.12-0.150.140.14
Short Term Investments
0.810.460.140.07-0.16-0.16-0.070.93-0.02-0.08-0.07-0.210.090.970.970.26-0.210.240.24
Intangible Assets
-0.41-0.13-0.41-0.070.810.82-0.1-0.2-0.31-0.03-0.09-0.21-0.63-0.03-0.04-0.210.3-0.78-0.78
Current Deferred Revenue
0.580.270.330.15-0.95-0.940.020.220.41-0.080.010.09-0.63-0.07-0.070.07-0.10.090.09
Net Invested Capital
0.740.460.00.050.030.03-0.110.92-0.1-0.11-0.110.97-0.03-0.071.00.19-0.150.110.11
Net Working Capital
0.740.460.010.050.020.02-0.110.92-0.1-0.1-0.10.97-0.04-0.071.00.22-0.150.120.12
Capital Stock
0.17-0.010.28-0.01-0.17-0.170.130.180.060.110.120.26-0.210.070.190.22-0.020.290.29
Long Term Debt
-0.150.010.040.10.170.17-0.11-0.13-0.16-0.14-0.15-0.210.3-0.1-0.15-0.15-0.02-0.28-0.28
Capital Surpluse
0.12-0.050.35-0.02-0.4-0.40.140.110.120.130.140.24-0.780.090.110.120.29-0.281.0
Short Long Term Debt
0.12-0.050.35-0.02-0.4-0.40.140.110.120.130.140.24-0.780.090.110.120.29-0.281.0
Click cells to compare fundamentals

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Interest Income50 K47.5 K
Net Interest Income50 K52.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY